MRKR PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

MRKR ▲ +25.76% at T+20d

NEUTRAL call ✓ call won +25.76% · α vs SPY +18.14% · entry $1.32 → $1.66

Next anchor: T+60d in 2d

Currently $1.41 · +6.82% from $1.32 entry

Entry anchored
Mar 18, 03:59 PM ET
via Databento tick

T+1d

+1.52%

call +1.52% · α +3.26%

$1.34

settled 3mo ago

T+5d

+2.27%

call +2.27% · α +4.48%

$1.35

settled 3mo ago

T+20d

+25.76%

call +25.76% · α +18.14%

$1.66

settled 8w ago

T+60d

—

call — · α —

—

in 2d

Price Chart

Loading chart...

Executive Summary

Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.

Key Financial Metrics

Revenue

$3.5M

-46.2% YoY

Adj. EPS

$-12163620.00

GAAP: $-12163620.00

Actionable Insight

Traders should monitor the upcoming Q2 2026 clinical data readouts for MT-601 in lymphoma and the initiation of the pancreatic cancer trial, which could serve as near-term catalysts. However, declining grant revenue and persistent losses raise funding risk beyond 2026 without dilution or new grants.

Key Facts

Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
Cash runway expected through Q4 2026 without additional grant funding.
MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.
Nature Medicine publication reported up to 84.6% disease control rate in pancreatic cancer with MT-601 combination therapy.
Company-sponsored pancreatic cancer trial expected to initiate in Q2 2026.
Grant income declined sharply to $3.5M in 2025 from $6.6M in 2024.

Financial Impact

Revenue declined 46% YoY to $3.5M due to lower grant income; net loss increased 13% despite cost reductions; cash burn was $12.0M in 2025.

revenuenet_losscash_positiongrant_income

Risk Factors

Limited cash runway extending only to Q4 2026 with no guarantee of additional grant disbursements.
Heavy reliance on non-dilutive funding; decline in grant income raises sustainability concerns.
Clinical-stage biotech risk: value hinges on unproven therapies with no near-term revenue potential.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3258655

3 reports for MRKR

T+1T+5T+20T+60

Filters

Reports for MRKR — sortable, filterable
	Type				Now
Mar 20, 2026 11w ago	DEFA14A NEUTRAL ★ 4/10	$1.31 $1.56	▲ +19.08%	▲ +11.66%	$1.41 (+7.63%)
Mar 19, 2026 11w ago	8-K MIXED ★ 6/10	$1.32 $1.66	▲ +25.76%	▲ +18.14%	$1.41 (+6.82%)
Mar 18, 2026 11w ago	Press Release MIXED ★ 6/10	$1.32 $1.66	▲ +25.76%	▲ +18.14%	$1.41 (+6.82%)

US Market Status

Market Closed — Opens Thu (10h 59m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access